Polyrizon Ltd. (PLRZ)
About Polyrizon Ltd.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$3.3M
- Total assets
- $21.4M
- Market cap
- $24.3M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $24.3M
- Shares outstanding
- 1.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 29, 2024
Polyrizon Ltd. (PLRZ) Stock Price
- Reported a net loss of $3.3M.
- Trading 15% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Polyrizon Ltd..
Write a review
News about Polyrizon Ltd.
News & sentiment via Polygon.io
Polyrizon Ltd.: frequently asked questions
Is Polyrizon Ltd. an American company?
Polyrizon Ltd. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Polyrizon Ltd. publicly traded?
Yes — Polyrizon Ltd. is a publicly traded company. Its stock trades under the ticker symbol PLRZ on the NASDAQ.
What does Polyrizon Ltd. do?
Polyrizon Ltd. is an American Medical Devices company in the Health & Beauty sector.
